LYBALVI Drug Patent Profile

When do Lybalvi patents expire, and when can generic versions of Lybalvi launch?

Lybalvi is a drug marketed by Alkermes Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty countries.

The generic ingredient in LYBALVI is olanzapine; samidorphan l-malate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine; samidorphan l-malate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lybalvi

Lybalvi was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 31, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LYBALVI

International Patents:	60
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
Drug Prices:	Drug price information for LYBALVI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LYBALVI
What excipients (inactive ingredients) are in LYBALVI?	LYBALVI excipients list
DailyMed Link:	LYBALVI at DailyMed

See drug prices for LYBALVI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LYBALVI

Constraining patent/regulatory exclusivity:

10,300,054

NDA:

213378

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LYBALVI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alkermes, Inc.	Phase 1

See all LYBALVI clinical trials

Pharmacology for LYBALVI

Drug Class	Atypical Antipsychotic Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Paragraph IV (Patent) Challenges for LYBALVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LYBALVI	Tablets	olanzapine; samidorphan l-malate	5 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg	213378	3	2025-05-28

US Patents and Regulatory Information for LYBALVI

LYBALVI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,300,054.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No	11,707,466		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,351,166
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,241,425

Expired US Patents for LYBALVI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021	7,262,298
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021	7,956,187

International Patents for LYBALVI

When does loss-of-exclusivity occur for LYBALVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Japan

Lithuania

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LYBALVI around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2304477
Spain	2705726
European Patent Office	3446565	PROCÉDÉS POUR LE TRAITEMENT DE LA PRISE DE POIDS INDUITE PAR DES ANTIPSYCHOTIQUES (METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN)
Japan	2013067636	4-HYDROXYBENZOMORPHAN

Supplementary Protection Certificates for LYBALVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927

LYBALVI (Olanzapine and Samidorphan) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Lybalvi, a fixed-dose combination of olanzapine and samidorphan, is approved for treating schizophrenia and bipolar I disorder in adults. The drug's market performance is influenced by its efficacy, safety profile, competitive landscape, and intellectual property protection. Understanding these factors is critical for evaluating its financial trajectory and R&D investment potential.

What is the Regulatory Status of Lybalvi?

Lybalvi received U.S. Food and Drug Administration (FDA) approval on June 17, 2021, for the treatment of schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder in adults, as a monotherapy and as an adjunct to lithium or valproate [1]. In the European Union, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Lybalvi in May 2023, for schizophrenia in adults and for moderate to severe manic or mixed episodes in bipolar I disorder in adults, following a response to an opinion [2]. The European Medicines Agency (EMA) granted marketing authorization in July 2023 [2].

What is the Intellectual Property Landscape for Lybalvi?

The patent portfolio for Lybalvi is a key determinant of its market exclusivity and future revenue streams. Key patents include those covering the fixed-dose combination itself, specific formulations, and methods of use.

• Composition of Matter Patents: These patents, typically covering the novel combination of olanzapine and samidorphan, offer the strongest protection.
• Formulation Patents: These patents protect specific delivery systems or pharmaceutical compositions that may offer improved pharmacokinetic profiles or patient convenience.
• Method of Use Patents: These patents cover the use of Lybalvi for specific indications, such as schizophrenia or bipolar disorder, and can extend market exclusivity beyond the expiration of composition of matter patents.

The expiration dates of these patents are crucial for forecasting the onset of generic competition. For instance, U.S. Patent No. 9,949,905, which is a key patent for Lybalvi, is listed as expiring in 2034 [3]. However, patent litigation and the potential for extensions, such as U.S. Patent Term Extensions (PTE) under the Hatch-Waxman Act, can alter the effective market exclusivity period.

How Does Lybalvi Differentiate Itself in the Market?

Lybalvi's differentiation strategy hinges on addressing unmet needs in the treatment of schizophrenia and bipolar disorder, particularly regarding weight gain, a common side effect of many atypical antipsychotics.

• Mechanism of Action: Lybalvi combines olanzapine, a well-established antipsychotic, with samidorphan. Samidorphan is a mu-opioid receptor antagonist that is believed to mitigate olanzapine-induced weight gain and metabolic changes [4]. This dual action aims to provide therapeutic efficacy while improving the metabolic safety profile.
• Clinical Trial Data: Clinical trials, such as the ENLIGHTEN program, have demonstrated Lybalvi's efficacy in treating schizophrenia and bipolar I disorder. The trials also provided data on weight changes compared to placebo and olanzapine alone. For example, in one Phase III study for schizophrenia, patients treated with Lybalvi experienced significantly less weight gain compared to those treated with olanzapine alone [5]. This metabolic benefit is a primary selling point.
• Patient Profile: Lybalvi is indicated for adult patients requiring treatment for schizophrenia or bipolar I disorder. Its potential to reduce weight gain may appeal to patients and physicians concerned about the metabolic side effects of other antipsychotic medications.

What is the Competitive Landscape for Lybalvi?

The market for antipsychotic medications is highly competitive, with numerous branded and generic products available. Lybalvi competes against both established atypical antipsychotics and newer agents.

• Established Atypical Antipsychotics: These include olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel), aripiprazole (Abilify), and ziprasidone (Geodon). Many of these have generic versions available, leading to significant price competition.
• Newer Agents: Newer antipsychotics such as brexpiprazole (Rexulti), cariprazine (Vraylar), and lumateperone (Caplyta) offer different mechanisms of action and potentially improved side effect profiles, including less metabolic burden.
• Head-to-Head Comparisons: Lybalvi's primary competitive advantage is its ability to mitigate weight gain associated with olanzapine. Physicians will weigh this benefit against the efficacy and side effect profiles of other treatments. The cost-effectiveness of Lybalvi compared to managing metabolic comorbidities associated with other antipsychotics will also be a significant factor.

What is the Commercialization Strategy for Lybalvi?

Alkermes, the developer of Lybalvi, employs a targeted commercialization strategy focused on educating healthcare providers and patients about the drug's unique benefits.

• Target Audience: The primary target audience includes psychiatrists, neurologists, and other healthcare professionals who treat patients with schizophrenia and bipolar disorder.
• Marketing and Sales Efforts: Alkermes has established a sales force to promote Lybalvi. Marketing efforts emphasize the clinical trial data demonstrating efficacy and the mitigation of weight gain.
• Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is crucial for market access. Alkermes aims to demonstrate the value proposition of Lybalvi, including potential cost savings from avoiding weight-related comorbidities.
• Geographic Rollout: Following U.S. approval, the commercialization strategy includes a phased rollout in other key markets, such as Europe, following regulatory approvals.

What is the Financial Performance and Outlook for Lybalvi?

The financial trajectory of Lybalvi is contingent on its adoption rate, market penetration, and pricing strategy, balanced against the cost of sales and marketing.

• Revenue Projections: While specific revenue figures for Lybalvi are often embedded within Alkermes' broader financial reporting, early adoption trends and market penetration estimates by analysts provide insights. For example, following its launch in late 2021, analysts have projected peak sales for Lybalvi.
• Sales Performance (Examples):
  • Alkermes reported Lybalvi net sales of $36 million for the first quarter of 2023 [6].
  • For the full year 2022, Lybalvi net sales were $95.1 million [7].
  • This represents a significant increase from the $27.4 million in sales recorded in 2021, the drug's launch year [7].
• Factors Influencing Future Revenue:
  • Market Penetration: The rate at which physicians prescribe Lybalvi and patients initiate treatment.
  • Competitor Activity: The launch of new competitors or increased marketing of existing ones.
  • Patent Expirations: The impending threat of generic competition following patent expiry.
  • Reimbursement Landscape: Changes in payer policies that could affect patient access and affordability.
  • Lifecycle Management: Potential for new indications or formulations that could extend market exclusivity.

What are the Key Challenges and Opportunities for Lybalvi?

Lybalvi faces a complex market environment with both significant opportunities and notable challenges.

Challenges

• Established Generic Competition: The market for antipsychotics has a long history of generic penetration, which drives down prices for older molecules.
• Physician Inertia: Prescribing habits can be slow to change, particularly with established treatments that have a known track record, even with known side effects.
• Market Access and Reimbursement Hurdles: Gaining broad formulary acceptance and favorable reimbursement terms can be a lengthy and challenging process.
• Perception of Samidorphan: While designed to mitigate weight gain, the long-term effects and perceived benefits of samidorphan may require continued education and evidence generation.
• Post-Launch Data Requirements: Ongoing pharmacovigilance and the need to generate real-world evidence to support the drug's long-term value proposition.

Opportunities

• Addressing Unmet Needs: The significant unmet need for antipsychotics with a better metabolic profile remains a core opportunity.
• Physician and Patient Demand: Growing awareness among clinicians and patients about the metabolic burden of current treatments could drive Lybalvi adoption.
• Broader Indication Expansion: Potential for future clinical trials and approvals for other psychiatric conditions where weight gain is a concern.
• International Market Expansion: Successful launches in Europe and other key global markets can significantly expand revenue potential.
• Lifecycle Management: Development of novel delivery systems or combination therapies involving samidorphan could extend the product's life cycle.

Key Takeaways

Lybalvi's market position is defined by its differentiated approach to managing weight gain associated with antipsychotic therapy. Its regulatory approvals in key markets provide a foundation for commercialization. Intellectual property protection, particularly through patents extending into the mid-2030s, offers a defined period of market exclusivity. However, the drug operates within a highly competitive and price-sensitive antipsychotic market. Alkermes' commercialization strategy focuses on highlighting Lybalvi's metabolic benefits to a targeted prescriber base. Financial performance has shown a growth trajectory since its launch, with net sales increasing year-over-year. Future revenue will depend on market penetration, competitive pressures, and the ability to secure favorable reimbursement. The primary challenges include overcoming physician inertia and navigating market access hurdles, while opportunities lie in addressing the persistent unmet need for metabolically favorable treatments and potential international expansion.

FAQs

1. What is the primary mechanism of action that differentiates Lybalvi from other antipsychotics? Lybalvi combines olanzapine with samidorphan. Samidorphan is a mu-opioid receptor antagonist intended to mitigate olanzapine-induced weight gain and metabolic changes, a common side effect of many atypical antipsychotics.

2. When did Lybalvi receive FDA approval, and for which indications? Lybalvi received FDA approval on June 17, 2021, for the treatment of schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder in adults.

3. What are the projected patent expiry dates that will impact Lybalvi's market exclusivity? Key patents, such as U.S. Patent No. 9,949,905, are listed as expiring in 2034. However, patent term extensions and potential litigation can alter the actual period of market exclusivity.

4. What were Lybalvi's net sales in the most recently reported full fiscal year? For the full year 2022, Lybalvi net sales were $95.1 million.

5. Which specific patient populations is Lybalvi indicated for? Lybalvi is indicated for adult patients diagnosed with schizophrenia and for adults experiencing manic or mixed episodes associated with bipolar I disorder.

Citations

[1] U.S. Food & Drug Administration. (2021, June 17). FDA approves Lybalvi (olanzapine and samidorphan) tablets for the treatment of schizophrenia and bipolar I disorder. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lybalvi-olanzapine-and-samidorphan-tablets-treatment-schizophrenia-and-bipolar-i-disorder

[2] European Medicines Agency. (2023, July 21). Lybalvi. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/lybalvi

[3] Alkermes plc. (2023). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission.

[4] Lally, N., & Kotecha, J. (2022). Olanzapine-samidorphan fixed-dose combination (Lybalvi): A review of its use in the management of schizophrenia. Drug Design, Development and Therapy, 16, 1887–1897. https://doi.org/10.2147/DDDT.S328908

[5] Alkermes. (2020, June 10). Alkermes announces FDA acceptance of New Drug Application for ALKS 3831 for the treatment of schizophrenia. Retrieved from https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-acceptance-new-drug-application-alks-3831

[6] Alkermes plc. (2023, April 26). Alkermes announces first quarter 2023 financial results. Retrieved from https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-first-quarter-2023-financial-results

[7] Alkermes plc. (2023). First Quarter 2023 Earnings Call Transcript. Retrieved from https://seekingalpha.com/article/4595352-alkermes-plc-qkrm-ceo-richard-pauley-on-q1-2023-results-earnings-call-transcript